Skip to main content

Catalyst Calendar

Scope

Mon, Oct 5, 2026

1 updates
IVVD
7:01 AM

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee’s

invivyd.com

Tue, Sep 29, 2026

1 updates
IVVD
7:01 AM

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccine VYD2311 combined with an mRNA-based

Trial Results • Phase 3LIBERTY Phase 3 topline results Tue, Sep 29, 2026invivyd.com

Tue, Sep 8, 2026

1 updates
IVVD
7:01 AM

Invivyd to Participate in Upcoming September Investor Conferences

NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences: Citi’s 2026 Biopharma Back to School Conference

invivyd.com

Thu, Sep 3, 2026

1 updates
IVVD
7:01 AM

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 255,000 shares of its common stock, each as a material inducement for each

invivyd.com

Tue, Sep 1, 2026

1 updates
IVVD
7:01 AM

Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY

Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director Ian Sheffield appointed to

Trial Results • Phase 3Top-line data Wed, Sep 30, 2026invivyd.com

Thu, Aug 13, 2026

1 updates
IVVD
4:05 PM

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q2 2026 PEMGARDA ® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demand

Enrollment • Phase 3Enrollment milestone Thu, Aug 13, 2026invivyd.com

Tue, Aug 4, 2026

1 updates
IVVD
7:01 AM

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on August 1, 2026, Invivyd granted ten newly hired non-executive employees options to purchase an aggregate of 277,500 shares of its common stock, each as a material inducement for each employee’s

invivyd.com